No abstract

No abstract

Clinical Therapeutics e50 Volume 39 Number 8S were eligible to be included. Both frequentist approach and Bayesian framework were used for analysis in R. Results: We included 7 RCTs with altogether 62268 T2DM patients in our network meta-analysis. GLP-1 RAs and the SGLT-2 inhibitor reduced MACE (OR 0.89, 0.82-0.97 and 0.85, 95%CI 0.73-0.99, respectively) and all-cause mortality (0.89, 0.80-0.99 and 0.67, 0.55-0.81, respectively) when compared to placebo. The SGLT-2 inhibitor reduced all-cause mortality more than GLP-1 RAs (OR 0.76, 95%CI 0.61-0.94). Moreover, DPP-4 inhibitors were comparable to placebo but associated with increased allcause mortality when compared to the SGLT-2 inhibitor (1.53, 1.24-1.89) and GLP-1 RAs (1.16, 1.01-1.33), respectively. Conclusions: The SGLT-2 inhibitor and GLP-1 RAs reduced all-cause mortality and MACE, which were both superior to DPP-4 inhibitors. The SGLT-2 inhibitor was more beneficial in preventing deaths than the other two drugs classes, which can be used as the prior secondline treatment for T2DM patients to reduce cardiovascular risks.